|
Vaccine, Rubella (MERUVAX®II)
CATEGORY: C
Live attenuated virus vaccine.
No evidence of congenital rubella syndrome occurred in the offspring of the 226 women who
received the current RA 27/3 rubella vaccine and continued their pregnancy to term. Nonetheless women should be counseled to avoid becoming
pregnant for 28 days after exposure to rubella-containing vaccines [1,2].
BREAST FEEDING: Excreted into human milk. Recent studies have shown that
lactating postpartum women immunized with live attenuated rubella vaccine may
secrete the virus in breast milk and transmit it to breast-fed infants. In the
infants with serological evidence of rubella infection, none exhibited severe
disease; however, one exhibited mild clinical illness typical of acquired
rubella. Caution should be exercised when MERUVAX II is administered to a
nursing woman [3]. Compatible with breastfeeding [4,5].
SEARCH LITERATURE
1.Centers for Disease Control & Prevention. Measles, Mumps, and Rubella — Vaccine Use and
Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of
Mumps: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 47
(No. RR-8): 32-33, 1998.
2.
Revised ACIP Recommendation for Avoiding Pregnancy After Receiving a Rubella-Containing Vaccine
MMWR 50(49);1117, 2001
3.MeruvaxII®
vaccine package insert, 2001.
4.
Immunization: Recommendations of the Advisory Committee on Immunization
Practices (ACIP). MMWR 43 (No. RR-1): 20-21, 1994.
5.Breastfeeding and Maternal Medication.
Recommendations for Drugs in the Eleventh WHO Model list of Essential Drugs. pp
23-24 World Health Organization, 2002. 20 Avenue Appia ,1211 Geneva ,Switzerland
(PDF file)
Created: 11/27/2002
Last Update: 11/30/2003
|
|
|
